These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 34948100)
21. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells. Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653 [TBL] [Abstract][Full Text] [Related]
22. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690 [TBL] [Abstract][Full Text] [Related]
24. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341 [TBL] [Abstract][Full Text] [Related]
25. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Bai RY; Esposito D; Tam AJ; McCormick F; Riggins GJ; Wade Clapp D; Staedtke V Gene Ther; 2019 Jun; 26(6):277-286. PubMed ID: 31127187 [TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2. Patrakitkomjorn S; Kobayashi D; Morikawa T; Wilson MM; Tsubota N; Irie A; Ozawa T; Aoki M; Arimura N; Kaibuchi K; Saya H; Araki N J Biol Chem; 2008 Apr; 283(14):9399-413. PubMed ID: 18218617 [TBL] [Abstract][Full Text] [Related]
27. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Shapira S; Barkan B; Friedman E; Kloog Y; Stein R Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025 [TBL] [Abstract][Full Text] [Related]
28. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1. Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368 [TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice. Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393 [TBL] [Abstract][Full Text] [Related]
30. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Dilworth JT; Wojtkowiak JW; Mathieu P; Tainsky MA; Reiners JJ; Mattingly RR; Hancock CN Cancer Biol Ther; 2008 Dec; 7(12):1938-46. PubMed ID: 18927496 [TBL] [Abstract][Full Text] [Related]
31. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Ki DH; He S; Rodig S; Look AT Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693 [TBL] [Abstract][Full Text] [Related]
32. Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1. Staedtke V; Gray-Bethke T; Riggins GJ; Bai RY Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32650362 [TBL] [Abstract][Full Text] [Related]
33. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110 [TBL] [Abstract][Full Text] [Related]
35. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323 [TBL] [Abstract][Full Text] [Related]
36. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
37. MiR-27a-3p/miR-27b-3p Promotes Neurofibromatosis Type 1 via Targeting of NF1. Lu H; Liu P; Pang Q J Mol Neurosci; 2021 Nov; 71(11):2353-2363. PubMed ID: 33570696 [TBL] [Abstract][Full Text] [Related]
38. Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. Brossier NM; Prechtl AM; Longo JF; Barnes S; Wilson LS; Byer SJ; Brosius SN; Carroll SL J Neuropathol Exp Neurol; 2015 Jun; 74(6):568-86. PubMed ID: 25946318 [TBL] [Abstract][Full Text] [Related]
39. Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Miller SJ; Li H; Rizvi TA; Huang Y; Johansson G; Bowersock J; Sidani A; Vitullo J; Vogel K; Parysek LM; DeClue JE; Ratner N Mol Cell Biol; 2003 Mar; 23(6):2213-24. PubMed ID: 12612091 [TBL] [Abstract][Full Text] [Related]